PH009 / Suzhou Puhe Pharma - LARVOL DELTA

PH009-1, a highly potent, selective and brain-penetrable fourth-generation EGFR-TKI that overcome classic and resistant EGFR mutations in NSCLC (AACR 2024) - "Background: Epidermal growth factor receptor (EGFR) inhibitors, especially 3rd Gen inhibitor such as osimertinib (Osi), have become the first line therapy for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations...In recent years, 4th Gen EGFR inhibitors have been developed such as BLU-945 and PH009-1... Our data suggested that PH009-1 overcome T790M/C797S resistant mutations, and also have potential to become a potent and safe approach for first line therapy of NSCLC with EGFR mutations."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: Suzhou Puhe Pharmaceutical Technology Co., LTD

Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor